Arrowhead Pharmaceuticals Clears Regulatory Hurdle With First Approval for Plozasiran in FCS

Arrowhead Pharmaceuticals has received its first approval for plozasiran, an siRNA therapy for Familial Chylomicronemia Syndrome in adults. This marks a significant milestone for the company, which has one of the longest-tailed pipelines in the pre-commercial stage. The approval paves the way for the treatment of a rare and debilitating genetic disorder.